These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38724960)

  • 1. Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China.
    Wang L; Huo X; Sun H; Liu F; Huang R; Zhao Q
    BMC Public Health; 2024 May; 24(1):1275. PubMed ID: 38724960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China.
    Chen P; Wang Y; Liu X; Yu J; Zheng X
    Am J Cardiovasc Drugs; 2024 May; 24(3):445-454. PubMed ID: 38619802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
    Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
    Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.
    Alsumali A; Djatche LM; Briggs A; Liu R; Diakite I; Patel D; Wang Y; Lautsch D
    Pharmacoeconomics; 2021 Nov; 39(11):1343-1354. PubMed ID: 34623625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
    Chew DS; Li Y; Bigelow R; Cowper PA; Anstrom KJ; Daniels MR; Davidson-Ray L; Hernandez AF; O'Connor CM; Armstrong PW; Mark DB;
    Circulation; 2023 Oct; 148(14):1087-1098. PubMed ID: 37671551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.
    Alsumali A; Lautsch D; Liu R; Patel D; Nanji S; Djatche LM
    Adv Ther; 2021 May; 38(5):2631-2643. PubMed ID: 33860924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.
    Mentz RJ; Stebbins A; Butler J; Chiang CE; Ezekowitz JA; Hernandez AF; Hilkert R; Lam CSP; McDonald K; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Sweitzer NK; Voors AA; Anstrom KJ; Armstrong PW;
    JACC Heart Fail; 2024 May; 12(5):839-846. PubMed ID: 38363272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
    Lam CSP; Giczewska A; Sliwa K; Edelmann F; Refsgaard J; Bocchi E; Ezekowitz JA; Hernandez AF; O'Connor CM; Roessig L; Patel MJ; Pieske B; Anstrom KJ; Armstrong PW;
    JAMA Cardiol; 2021 Jun; 6(6):706-712. PubMed ID: 33185650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials.
    Lou Y; Yu Y; Liu J; Huang J
    Front Public Health; 2022; 10():959139. PubMed ID: 36062091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients.
    Tian L; Fu S; Li M; Zhao X; Li H
    Front Public Health; 2023; 11():1196789. PubMed ID: 38145082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction.
    Tang Y; Sang H
    ESC Heart Fail; 2023 Aug; 10(4):2524-2533. PubMed ID: 37290665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis.
    Yang H; Li N; Zhou Y; Xiao Z; Tian H; Hu M; Li S
    Drug Des Devel Ther; 2020; 14():157-165. PubMed ID: 32021100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS; Tolppanen H
    Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
    Liang L; Bin-Chia Wu D; Aziz MIA; Wong R; Sim D; Leong KTG; Wei YQ; Tan D; Ng K
    J Med Econ; 2018 Feb; 21(2):174-181. PubMed ID: 28959905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
    Lou Y; Hu T; Huang J
    Am J Cardiovasc Drugs; 2023 Jan; 23(1):47-57. PubMed ID: 36207658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
    Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
    J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China.
    Cao W; Yu Y; Qiu Y; Liu L; Zhang H; Shi L; Xiao Y; Jia L; Zhang R; Wang X
    BMC Health Serv Res; 2022 Dec; 22(1):1580. PubMed ID: 36567324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.